Tevogen bio's effort in artificial intelligence, tevogen ai, joins microsoft for startups, begins accelerating drug development

Warren, n.j., oct. 23, 2024 (globe newswire) -- tevogen bio (“tevogen” or “tevogen bio holdings inc.”) (nasdaq: tvgn), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified t cell therapeutics to treat infectious disease and cancers, announces its artificial intelligence effort, tevogen ai, has joined microsoft (nasdaq: msft) for startups. this partnership marks a significant milestone for tevogen, providing unparalleled access to microsoft's extensive ecosystem. the partnership is set to accelerate and streamline the development of tevogen's proprietary algorithms, significantly advancing our mission to lower the total cost of drug development, expedite drug discovery, and deliver life-changing therapies to large patient populations.
MSFT Ratings Summary
MSFT Quant Ranking